XML 22 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 19, 2025
Document Information [Line Items]    
Document Type 10-K  
Amendment Flag false  
Document Period End Date Dec. 31, 2024  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus FY  
Current Fiscal Year End Date --12-31  
Document Annual Report true  
Document Transition Report false  
Entity File Number 001-42179  
Entity Registrant Name Artiva Biotherapeutics, Inc.  
Entity Central Index Key 0001817241  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 83-3614316  
Entity Address, Address Line One 5505 Morehouse Drive  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town San Diego  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92121  
City Area Code 858  
Local Phone Number 267-4467  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol ARTV  
Security Exchange Name NASDAQ  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
ICFR Auditor Attestation Flag false  
Document Financial Statement Error Correction [Flag] false  
Documents Incorporated by Reference [Text Block]

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive proxy statement relating to its 2025 annual meeting of shareholders (the Proxy Statement) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.

  
Entity Public Float $ 0  
Entity Common Stock, Shares Outstanding   24,363,119
Auditor Name KPMG LLP  
Auditor Firm ID 185  
Auditor Location San Diego, California  
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Artiva Biotherapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.